2022 BO42452 – A Phase Ib, Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso Occlusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD) Case StudiesOngoing 2022 BO42452 – A Phase Ib, Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso Occlusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD)
2022 BO42451 – A Randomized Double-Blind Phase IIa Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Vaso-Occlusive Episodes (Voe) In Sickle Cell Disease (SCD) Case StudiesOngoing 2022 BO42451 – A Randomized Double-Blind Phase IIa Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Vaso-Occlusive Episodes (Voe) In Sickle Cell Disease (SCD)
2012 TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2012 TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease
2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease
2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease Case StudiesClosed out 2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease
2019 HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease Case StudiesClosed out 2019 HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease
2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease Case StudiesClosed out 2017 GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT 440 Administered Orally to Patients with Sickle Cell Disease
2018 GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials (GBT440-034) Case StudiesOngoing 2018 GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials (GBT440-034)
2020 IMR-SCD-301 ‘IMARA’ – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease Case StudiesClosed out 2020 IMR-SCD-301 ‘IMARA’ – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
2021 GBT440-032 “HOPE Kids 2” – A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Paediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease Case StudiesOngoing 2021 GBT440-032 “HOPE Kids 2” – A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Paediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease
